加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.89
−US$0.0256 · -2.80%
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
常规交易时段
US$0.89
−US$0.0256 · -2.80%
盘中时间采用ET。市场数据可能有所延迟。
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
日内区间
当前US$0.89
52周区间
当前US$0.89
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
49
合理估值
情绪
55
多空交织
风险
85
极高风险
动量
27
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
日内区间
当前US$0.89
52周区间
当前US$0.89
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 100.55万 USD | 60.76万 USD | 25.36万 USD | 22.32万 USD | 116.03万 USD |
| 销货成本 | 78.17万 USD | 38.48万 USD | 47.46万 USD | 43.24万 USD | 85.07万 USD |
| 毛利 | 22.38万 USD | 22.28万 USD | −22.1万 USD | −20.92万 USD | 30.96万 USD |
| 研究与开发 | 210.62万 USD | 498.65万 USD | 69.18万 USD | 52.56万 USD | 551.09万 USD |
| 销售、一般及管理费用 | 627.98万 USD | 502.5万 USD | 424.18万 USD | 130.37万 USD | 111.54万 USD |
| 营业费用 | 798.24万 USD | 993.77万 USD | 493.36万 USD | 154.13万 USD | 143.37万 USD |
| 利息支出 | 7805 USD | 7912 USD | 228.66万 USD | 398.94万 USD | 317.27万 USD |
| 折旧和摊销 | 8.29万 USD | 6.37万 USD | 10.04万 USD | 7.88万 USD | 7.18万 USD |
| 营业利润 | −775.86万 USD | −971.49万 USD | −515.46万 USD | −175.04万 USD | −112.41万 USD |
| 净利润 | −736.83万 USD | −794.71万 USD | −376.57万 USD | −618.17万 USD | −425.17万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年1月20日 | 1:4 | — | — |
股票拆分 | 2025年2月24日 | 1:5 | — | — |
股票拆分 | 2024年8月12日 | 1:12 | — | — |
已生效 2026年1月20日
1:4
已生效 2025年2月24日
1:5
已生效 2024年8月12日
1:12
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
